Bellicum Pharmaceuticals, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
079481404
SEDOL
N/A
CIK
0001358403
www.bellicum.com
LEI:
©
FIGI: BBG00DLMHKX0
BLCM
Bellicum Pharmaceuticals, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Bellicum Pharmaceuticals, Inc.
ISIN
US0794814048
TICKER
BLCM
MIC
XNAS
REUTERS
BLCM.OQ
BLOOMBERG
BLCM US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
This section is currently still under construction. If you are interested in short-selling statistics, you can find out here, for example.
Track all markets on TradingView
Click here for comprehensive price and chart analyses
EN 728x90
smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

RNS-News: Temporary or permanent suspension of the stock exchange listing.
At the moment it is not possible to render the historical price development in the form of a chart. But don't worry: you can use the stock market symbol, TV icon or the button panel below the chart window to select alternative sources for further research.
BLCM
The charts are provided by TradingView. Millions of investors use the innovative tools and solutions. If you are interested in professional tools, e.g. in the field of technical analysis, you are sure to find what you are looking for here.
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.